Cullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial ResultsGlobeNewsWire • 03/17/22
Cullinan Oncology to Host CLN-081 Regulatory Update Webinar on March 28, 2022GlobeNewsWire • 03/17/22
Cullinan Oncology to Present Data Demonstrating Breadth and Progress of Its Immuno-Oncology Portfolio at AACR 2022GlobeNewsWire • 03/08/22
Cullinan Oncology Expands Leadership Team and Board of Directors with Appointments of Jeffrey Jones, M.D., MPH, MBA to Chief Medical Officer and Anne-Marie Martin Ph.D.GlobeNewsWire • 02/28/22
Cullinan Oncology to Present at SVB Leerink's 11th Annual Global Healthcare ConferenceGlobeNewsWire • 02/07/22
Cullinan Oncology Forms Strategic Collaboration Agreement with Mount Sinai to Advance Oral HPK1 Protein Degrader for Cancer TreatmentGlobeNewsWire • 01/10/22
Cullinan Oncology stock shoots higher after lung cancer treatment granted BTD by FDAMarket Watch • 01/04/22
FDA Grants Breakthrough Therapy Designation for Cullinan Oncology's CLN-081 in Patients with Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung CancerGlobeNewsWire • 01/04/22
Cullinan Oncology Announces Updated Phase 1/2a Data for CLN-081 in NSCLC EGFR Exon 20 PatientsGlobeNewsWire • 12/16/21
Cullinan Oncology to Provide Clinical Update for CLN-081 in NSCLC EGFR Exon 20 PatientsGlobeNewsWire • 12/13/21
Cullinan Oncology to Participate in the Evercore ISI 4th Annual HealthconX ConferenceGlobeNewsWire • 11/22/21
Cullinan Oncology Provides Corporate Update and Reports Third Quarter 2021 Financial ResultsGlobeNewsWire • 11/09/21
Cullinan Oncology Provides Corporate Update and Reports Second Quarter 2021 Financial ResultsGlobeNewsWire • 08/10/21
Cullinan Oncology Receives Investigational New Drug (IND) Clearance from the FDA for CLN-049, a FLT3 x CD3 Bispecific Antibody for the Treatment of Relapsed/Refractory AMLGlobeNewsWire • 06/07/21
Cullinan Oncology Announces Phase 1/2a Interim Data For Cullinan Pearl's CLN-081 in NSCLC EGFR Exon 20 PatientsGlobeNewsWire • 06/04/21